Gradient Investments’s Filana Therapeutics FLNA Stock Holding History

Gradient Investments’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-400	Closed	-$9.65K	–	1867
2023 Q1	$9.65K	Buy	+400	New	+$11.1K	﹤0.01%	822

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Gradient Investments's FLNA Position: Q2 2023 in Review

Gradient Investments sold out of Filana Therapeutics (FLNA) in Q2 2023, closing a stake of 400 shares — an estimated $9.65K sold.

Gradient Investments first reported a position in FLNA in Q1 2023 and held it in 1 quarter. The position peaked at $9.65K in Q1 2023. 152 funds tracked by Wall St. Rank hold FLNA as of Q2 2023.

Gradient Investments reported no remaining Filana Therapeutics position as of Q2 2023 after selling out during the quarter.
Gradient Investments sold 400 Filana Therapeutics shares in Q2 2023, an estimated $9.65K.
Gradient Investments first reported a position in Filana Therapeutics in Q1 2023 and held it in 1 quarter.
Gradient Investments's Filana Therapeutics position peaked at $9.65K in Q1 2023.
152 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2023.

Based on Gradient Investments's 13F filing for Q2 2023, filed 11 Jul 2023.